Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC) (ASCO 2018)

Ruihua Xu, Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Ye Hua, Weiguo Su, Shukui Qin

 HMPL-013_Ph3_CRC_Subgroup_ASCO_2018_thumb

 

Venue: American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA

Abstract #: 3537

Session: Poster Session – Gastrointestinal (Colorectal) Cancer

Date: Sunday, June 3, 08:00 – 11:30 CDT

Location: Exhibit Hall A, McCormick Place

 

Download Poster (PDF)